Compliance with tuberculosis preventive therapy in a randomized placebo-controlled trial in 2736 HIV-infected Ugandans was measured using urinary isoniazid metabolite testing, clinic attendance, and self-report.
Overall, 77% of urine tests were positive, subjects kept 85% of their scheduled visits while on therapy, and 69% reportedly never forgot to take their medication.
Different strategies were used for constructing three composite compliance indices in active arms :
(1) an unweighted index of the summed scores on scaled compliance measures ;
(2) a weighted index using weights obtained from a survey of experts on tuberculosis ;
and (3) a statistically weighted index using principal components analysis.
Composite indices were evaluated for reliability, validity, and practical utility.
Understanding of the regimen, study arm, subsequent follow-up, tuberculosis status, and urine spot-check result were associated with composite compliance scores.
The unweighted index in this study performed as well as the weighted indices.
Mots-clés Pascal : Tuberculose, Mycobactériose, Bactériose, Infection, Isoniazide, Antituberculeux, SIDA, Virose, Virus immunodéficience humaine, Lentivirus, Retroviridae, Virus, Epidémiologie, Chimiothérapie, Traitement, Efficacité traitement, Homme, Essai thérapeutique contrôlé, Etude comparative, Prévention, Immunopathologie, Immunodéficit, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Tuberculosis, Mycobacterial infection, Bacteriosis, Infection, Isoniazid, Antituberculous agent, AIDS, Viral disease, Human immunodeficiency virus, Lentivirus, Retroviridae, Virus, Epidemiology, Chemotherapy, Treatment, Treatment efficiency, Human, Controlled therapeutic trial, Comparative study, Prevention, Immunopathology, Immune deficiency, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0452340
Code Inist : 002B05C02D. Création : 25/01/1999.